TGF beta receptor antagonist + ASGR1 antibody conjugate (Silverback Therapeutics)

N/A

ๆŠฅๅ‘Šๆ—ถ้—ด: 2025/02/01 20:00:06

ๅŸบๆœฌไฟกๆฏ

่ฏ็‰ฉๅ็งฐTGF beta receptor antagonist + ASGR1 antibody conjugate (Silverback Therapeutics)
่ฏ็‰ฉๅˆซ็งฐASGR1-TGFbetaR
่ฏ็‰ฉ็ฑปๅž‹็”Ÿ็‰ฉ่ฏ > ่›‹็™ฝ็ฑป่ฏ็‰ฉ > ๅ…็–ซ็ƒ่›‹็™ฝ > ๆŠ—ไฝ“ > ๆŠ—ไฝ“็ผ€ๅˆ็‰ฉ > ๅ•ๅ…‹้š†ๆŠ—ไฝ“็ผ€ๅˆ็‰ฉ็”Ÿ็‰ฉ่ฏ > ่›‹็™ฝ็ฑป่ฏ็‰ฉ > ๅ…็–ซ็ƒ่›‹็™ฝ > ๆŠ—ไฝ“ > ๅ•ๅ…‹้š†ๆŠ—ไฝ“ > ๅ•ๅ…‹้š†ๆŠ—ไฝ“็ผ€ๅˆ็‰ฉ็”Ÿ็‰ฉ่ฏ > ่›‹็™ฝ็ฑป่ฏ็‰ฉ > ๅ…็–ซ็ƒ่›‹็™ฝ > ๆŠ—ไฝ“ > ๆŠ—ไฝ“็ผ€ๅˆ็‰ฉ > ๆŠ—ไฝ“ๅถ่”่ฏ็‰ฉ๏ผˆADC๏ผ‰
ไฝœ็”จๆœบๅˆถ่ฝฌๅŒ–็”Ÿ้•ฟๅ› ๅญฮฒๅ—ไฝ“ๆ‹ฎๆŠ—ๅ‰‚ๅŽปๅ”พๆถฒ้…ธ็ณ–่›‹็™ฝๅ—ไฝ“-1่ฐƒ่Š‚ๅ‰‚
้ถ็‚นๅŽปๅ”พๆถฒ้…ธ็ณ–่›‹็™ฝๅ—ไฝ“-1่ฝฌๅŒ–็”Ÿ้•ฟๅ› ๅญฮฒๅ—ไฝ“
ๆฒป็–—้ข†ๅŸŸ / ้€‚ๅบ”็—‡่‚็กฌๅŒ–
ๅ…จ็ƒๆ‰นๅ‡†้€‚ๅบ”็—‡N/A
ไธญๅ›ฝๆ‰นๅ‡†้€‚ๅบ”็—‡N/A
้ฆ–ๆ‰นๅ›ฝๅฎถ/ๅŒบๅŸŸN/A
้ฆ–ๆ‰นๆ—ฅๆœŸN/A
ๅ›ฝๅฎถ/ๅŒบๅŸŸ็พŽๅ›ฝ
ๆ˜ฏๅฆๅคๆ–นๅฆ
ๅ…จ็ƒๆœ€้ซ˜็ ”ๅ‘็Šถๆ€ๆ— ่ฟ›ๅฑ• (ไธดๅบŠๅ‰)
ไธญๅ›ฝๆœ€้ซ˜็ ”ๅ‘็Šถๆ€N/A
ๅŽŸ็ ”ๅ…ฌๅธSilverback Therapeutics Inc
ๆณจๅ†Œๅˆ†็ฑปN/A

็ ”ๅ‘ไฟกๆฏ

ๆดป่ทƒๅ…ฌๅธN/A
้žๆดป่ทƒๅ…ฌๅธSilverback Therapeutics Inc
ๆดป่ทƒ้€‚ๅบ”็—‡N/A
้žๆดป่ทƒ้€‚ๅบ”็—‡่‚็กฌๅŒ–

ๅ…ถไป–ไฟกๆฏ

ATCไปฃ็ N/A
็›ธๅ…ณ้“พๆŽฅN/A